alexa Comparison of Glycemic Control Indicators and Safety Evaluation during Linagliptin Treatment over 6 Months in Japanese Type 2 Diabetic Patients with and without Nephropathy
ISSN: 2155-6156

Journal of Diabetes & Metabolism
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Comparison of Glycemic Control Indicators and Safety Evaluation during Linagliptin Treatment over 6 Months in Japanese Type 2 Diabetic Patients with and without Nephropathy

Masami Tanaka*, Takeshi Nishimura, Risa Sekioka, Toshihide Kawai, Shu Meguro, Junichiro Irie, Yoshifumi Saisho and Hiroshi Itoh

Department of Internal Medicine, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan

*Corresponding Author:
Dr. Masami Tanaka
Department of Internal Medicine, School of Medicine
Keio University, 35 Shinanomachi, Shinjuku-ku
Tokyo 160- 8582, Japan
Tel: 81-3-5363-3797
Fax: 8133359-2745
E-mail: [email protected]

Received date: February 01, 2016 Accepted date: February 16, 2016 Published date: February 23, 2016

Citation: Tanaka M, Nishimura T, Sekioka R, Kawai T, Meguro S, et al. (2016) Comparison of Glycemic Control Indicators and Safety Evaluation during Linagliptin Treatment over 6 Months in Japanese Type 2 Diabetic Patients with and without Nephropathy. J Diabetes Metab 7:648. doi: 10.4172/2155-6156.1000648

Copyright: © 2016 Tanaka M, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.



Objective: This retrospective study was undertaken to compare hemoglobin A1c and glycoalbumin levels as glycemic control indicators during linagliptin treatment in diabetic patients with or without nephropathy. The efficacy and safety of linagliptin were also examined. Methods: The subjects were 127 outpatients with type 2 diabetes, including 69 patients with nephropathy. The hypoglycemic effect of linagliptin and the factors contributing to its hypoglycemic effect were examined. Several clinical parameters were compared before and after the initiation of linagliptin to evaluate the drug’s safety. Results: Linagliptin significantly decreased hemoglobin A1c and glycoalbumin levels at 3 and 6 months after treatment initiation. At 6 months, changes in hemoglobin A1c levels from baseline were strongly correlated with changes in glycoalbumin levels in diabetic patients with and without nephropathy. Changes in hemoglobin A1c and glycoalbumin at 6 months were significantly greater in patients with higher baseline values and shorter diabetes duration. Linagliptin decreased both hemoglobin A1c and glycoalbumin levels, irrespective of the baseline estimated glomerular filtration rate. No changes in clinical parameters thought to indicate adverse events were noted. Conclusions: Glycoalbumin is an equivalent glycemic control indicator and predictor to hemoglobin A1c during linagliptin treatment. Linagliptin is safe and effective in diabetic patients with or without nephropathy.


Share This Page

Additional Info

Loading Please wait..
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals


[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version